Abstract
Primary hepatobiliary malignancies include liver tumors, cholangiocarcinoma (CCA), and gallbladder carcinoma (GBC). The prognosis for hepatobiliary and pancreatic malignancies is dismal, with a 5-year survival rate ranging from 5% to 20%. Accurate detection, diagnosis, and staging may lead to more appropriate treatments and improved clinical outcomes. As surgical resection is the primary curative option for most hepatobiliary/pancreatic cancers, earlier and more correct detection may increase the likelihood of timely intervention [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lan BY, Kwee SA, Wong LL (2012) Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. Am J Surg 204:232–241.
Jadvar H (2012) Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers. Semin Nucl Med 42:247–254.
De Gaetano AM, Rufini V, Castaldi P et al (2012) Clinical applications of 18F-FDG-PET in the management of hepatobiliary and pancreatic tumors. Abdom Imaging 37:983–1003.
Sharma B, Martin A, Zerizer I (2013) Positron emission tomography-computed tomography in liver imaging. Semin Ultrasound CT MRI 34:66–80.
Sacks A, Peller PJ, Surasi DS et al (2011) Value of PET/CT in the management of primary hepatobiliary tumors, Part 2. AJR Am J Roentgenol 197:W260–W265.
Torizuka T, Tamaki N, Inokuma T et al (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36:1811–1817.
Shiomi S, Nishiguchi S, Ishizu H et al (2001) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 96:1877–1880.
Ho CL, Chen S, Yeung DW, Cheng TK (2007) Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 48:902–909.
Kawaoka T, Aikata H, Takaki S et al (2009) FDG positron emission tomography/computed tomography for the detection of extraepatic metastases from hepatocellular carcinoma. Hepatol Res 39:134–142.
D’Arienzo M, Chiaramida P, Chiacchiararelli L et al (2012) 90Y PET-based dosimetry after selective internal radiotherapy treatments. Nucl Med Commun 33:633–640.
Grassi I, Nanni C, Allegri V et al (2012) The clinical use of PET with (11)C-acetate. Am J Nucl Med Mol Imaging 2:33–47.
Delbeke D, Pinson CW (2003) 11C-acetate: a new tracer for the evaluation of hepatocellular carcinoma. J Nucl Med 2003; 44:222–223.
Petrowsky H, Wildbrett P, Husarik DB et al (2006) Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 45:43–50.
Kluge R, Schmidt F, Caca K et al (2001) Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 33:1029–1035.
Chung YE, Kim MJ, Park YN et al (2009) Varying appearance of cholangiocarcinoma: radiologic-pathologic correlation. RadioGraphics 29:673–700.
Klatskin G (1965) Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med 38:241–256.
Liver Cancer Study Group of Japan (1997) Classification of primary liver cancer. Kanehara, Tokyo.
Corvera CU, Blumgart LH, Akhurst T et al (2008) 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 206:57–65.
Fritscher-Ravens A, Bohuslavizki KH, Broering DC et al (2001) FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 22:1277–1285.
Chikamoto A, Tsuji T, Takamori H (2006) The diagnostic efficacy of FDG-PET in the local recurrence of hilar bile duct cancer. J Hepatobiliary Pancreat Surg 13:403–408.
Charbel H, Al-Kawas FH (2011) Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis. Curr Gastroenterol Rep 13:182–187.
Aljiffry M, Walsh MJ, Molinari M (2009) Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 15:4240–4262.
Valero V 3rd, Cosgrove D, Herman JM, Pawlik TM (2012) Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol 6:481–495.
Sahani DV, Bonaffini PA, Catalano OA et al (2012) State-of-the-Art PET/CT of the pancreas: current role and emerging in dications. RadioGraphics 32:1133–1158.
Rufini V, Baum RP, Castaldi P et al (2012) Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging 37:1004–1020.
Milan SA, Yeo CJ (2012) Neuroendocrine tumors of the pancreas. Curr Opin Oncol 24:46–55.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Fanti, S., Tabacchi, E., Svirydenka, H., Nanni, C. (2014). PET/CT in Hepatobiliary-Pancreatic Tumors. In: Hodler, J., von Schulthess, G.K., Kubik-Huch, R.A., Zollikofer, C.L. (eds) Diseases of the Abdomen and Pelvis 2014–2017. Springer, Milano. https://doi.org/10.1007/978-88-470-5659-6_31
Download citation
DOI: https://doi.org/10.1007/978-88-470-5659-6_31
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5658-9
Online ISBN: 978-88-470-5659-6
eBook Packages: MedicineMedicine (R0)